Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL: CRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Six‐minute walk distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in hospital admission (all‐cause): number of people admitted to hospital compared with usual care (low certainty).
2 findings from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in exacerbation: number of people experiencing one or more exacerbation compared with usual care (low certainty).
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in mortality compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
24 participants
GRADE not reported
Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review
Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found